Marinus Pharmaceuticals Inc (MRNS)
1.33
+0.03
(+2.31%)
USD |
NASDAQ |
May 17, 16:00
1.33
0.00 (0.00%)
After-Hours: 20:00
Marinus Pharmaceuticals Cash from Operations (TTM): -113.98M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -113.98M |
December 31, 2023 | -118.00M |
September 30, 2023 | -112.92M |
June 30, 2023 | -117.40M |
March 31, 2023 | -126.71M |
December 31, 2022 | -112.89M |
September 30, 2022 | -112.72M |
June 30, 2022 | -77.67M |
March 31, 2022 | -66.96M |
December 31, 2021 | -55.48M |
September 30, 2021 | -50.12M |
June 30, 2021 | -70.00M |
March 31, 2021 | -63.05M |
December 31, 2020 | -60.91M |
September 30, 2020 | -60.76M |
June 30, 2020 | -58.30M |
March 31, 2020 | -51.01M |
December 31, 2019 | -48.63M |
September 30, 2019 | -41.54M |
June 30, 2019 | -36.34M |
March 31, 2019 | -33.36M |
Date | Value |
---|---|
December 31, 2018 | -27.84M |
September 30, 2018 | -23.16M |
June 30, 2018 | -19.48M |
March 31, 2018 | -18.12M |
December 31, 2017 | -18.82M |
September 30, 2017 | -20.38M |
June 30, 2017 | -23.72M |
March 31, 2017 | -25.54M |
December 31, 2016 | -24.77M |
September 30, 2016 | -23.77M |
June 30, 2016 | -23.21M |
March 31, 2016 | -22.26M |
December 31, 2015 | -20.13M |
September 30, 2015 | -17.05M |
June 30, 2015 | -14.25M |
March 31, 2015 | -11.42M |
December 31, 2014 | -8.589M |
September 30, 2014 | -9.748M |
June 30, 2014 | -7.842M |
March 31, 2014 | -7.054M |
December 31, 2013 | -6.628M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-126.71M
Minimum
Mar 2023
-36.34M
Maximum
Jun 2019
-77.77M
Average
-65.00M
Median
Cash from Operations (TTM) Benchmarks
Pfizer Inc | 8.578B |
ACADIA Pharmaceuticals Inc | 63.71M |
Alnylam Pharmaceuticals Inc | 189.12M |
Regeneron Pharmaceuticals Inc | 4.739B |
Actinium Pharmaceuticals Inc | -39.63M |